P

Pfizer

Makes cancer drugs, vaccines and other medicines

Vaccines Category Lead

Full-TimePosted on 10/20/2026Deadline 11/4/26
No salary listed
Expert
Bachelor's, Master's, MBA
Cairo, Cairo Governorate, Egypt
In PersonTravel across Middle East markets as business needs require.
Growth & MarketingMarketing Generalist & Management

About the job

Requirements
  • A bachelor's degree in Life Sciences, Pharmacy, Medicine, Public Health, Business, or a related field is required.
  • Meaningful senior-level pharmaceutical or healthcare experience, with demonstrated leadership in vaccines, specialty care, portfolio management, marketing, or commercial roles.
  • Proven success leading complex portfolios, new launches, and cross-functional business priorities across multiple markets.
  • Strong understanding of vaccine markets, immunization systems, public-sector decision-making, and diverse customer and access pathways.
  • Demonstrated business and financial acumen, including operating planning, investment prioritization, forecasting, and performance management.
  • Ability to shape NIP and ecosystem opportunities in partnership with Medical, Access & Value, Policy & Public Affairs, and market teams.
  • Strong marketing leadership, customer-insight orientation, and experience building differentiated omnichannel strategies.
  • Enterprise mindset and ability to influence senior leaders and external stakeholders in a complex matrix.
  • Excellent analytical, communication, negotiation, and executive-presentation skills; fluency in English is required.
  • High standards of ethics, compliance, governance, and responsible stakeholder engagement.
Responsibilities
  • Own and translate the Middle East vaccines strategy into portfolio, brand, market, and customer priorities aligned with the cluster operating plan and growth agenda.
  • Lead end-to-end portfolio planning across established vaccines, growth assets, new indications, and future launches, balancing near-term delivery with long-term category value.
  • Set differentiated market strategies reflecting local epidemiology, immunization pathways, customer needs, access conditions, and competitive dynamics.
  • Establish category governance, operating rhythms, and performance reviews connecting regional strategy with market execution.
  • Own category business performance and provide direction on revenue, market share, investment, profitability, and resource-deployment priorities.
  • Lead annual operating-plan and long-range planning for the vaccines portfolio, including assumptions, scenarios, risks, and growth choices.
  • Prioritize advertising and promotion and commercial investments across assets and markets, reallocating resources toward high-impact opportunities.
  • Monitor performance and intervene when launch, demand, access, supply, or execution risks threaten category objectives.
  • Lead integrated launch strategy and readiness for new vaccines, indications, and presentations across Middle East markets.
  • Define launch ambition, sequencing, market archetypes, customer strategy, investment requirements, and critical success factors.
  • Build cross-functional launch plans spanning regulatory, medical, access, policy, supply, marketing, sales, and customer engagement.
  • Track launch readiness and post-launch performance through milestones and governance; accelerate decisions and remove execution barriers.
  • Identify and prioritize potential commercial opportunities for Pfizer vaccines arising from inclusion, expansion, or optimization of public-health immunization programs, and coordinate assessment and execution in accordance with Pfizer policies and procedures.
  • Partner with Access & Value, Medical, and Policy & Public Affairs to develop evidence-based value propositions and stakeholder engagement plans supporting commercial opportunities aligned with public-health immunization needs, in accordance with Pfizer policies and procedures.
  • Shape market-specific pathways addressing public-health needs, evidence requirements, funding considerations, procurement processes, and implementation readiness.
  • Maintain an enterprise view of commercial opportunities and risks across public-health immunization programs, supporting consistent strategic decisions and responsible market engagement in accordance with Pfizer policies and procedures.
  • Define and lead vaccine accelerators, including adult immunization, life-course vaccination, disease awareness, and priority ecosystem initiatives.
  • Select high-impact accelerators, establish sponsorship and governance, and define measurable business, access, and public-health outcomes.
  • Scale proven practices and reusable models across markets while adapting them to local healthcare systems and customer realities.
  • Use market, customer, and performance insights to test, learn, and redirect accelerator investments toward strong opportunities.
  • Lead, coach, and develop the Middle East vaccines marketing team, setting accountabilities across portfolio strategy, brand planning, launch management, and accelerator execution.
  • Ensure high-quality, insight-led brand plans and differentiated customer strategies for healthcare professionals, institutions, policymakers, and immunization stakeholders.
  • Partner with Commercial Excellence & AI to strengthen omnichannel engagement, analytics, content excellence, and marketing effectiveness.
  • Ensure marketing activities, claims, content, and customer engagement meet Pfizer standards for quality, compliance, and scientific integrity.
  • Partner with market and sales leaders to translate category strategy into executable local plans, with clear ownership and performance expectations.
  • Work with Medical to align evidence generation, scientific engagement, and education priorities with portfolio and launch needs.
  • Collaborate with Access & Value and Policy & Public Affairs to strengthen access pathways, value communication, and the enabling environment for immunization.
  • Align with Regulatory and Supply to anticipate approvals, demand, allocation, and continuity risks, protecting launch and in-line portfolio performance.
  • Build a high-performing, inclusive vaccines organization with strong capability in portfolio strategy, launch excellence, insight generation, and matrix leadership.
  • Develop talent through meaningful experiences, coaching, feedback, succession planning, and exposure to enterprise priorities.
  • Create clarity, accountability, and collaboration across marketing, vaccine accelerators, markets, and functions.
  • Promote a culture of courage, excellence, equity, and joy, with strong standards of ethics, compliance, and responsible business leadership.
  • Set strategic direction and portfolio priorities for the Middle East vaccines category within approved enterprise and cluster governance.
  • Recommend category operating-plan assumptions and determine allocation of approved marketing resources across brands, launches, accelerators, and markets.
  • Approve category brand plans, launch strategy, launch-readiness governance, and success measures.
  • Prioritize NIP opportunities and vaccine accelerators for senior sponsorship and cross-functional investment.
  • Hold the vaccines marketing organization accountable for execution quality, compliance, capability, and measurable business impact.
Desired Qualifications
  • An advanced degree such as an MBA, MPH, or MSc is preferred.
  • Arabic language proficiency is highly desirable.

About the company

Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
  • The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
  • Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.

What critics are saying

  • Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
  • Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
  • Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.

What makes Pfizer unique

  • Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
  • Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
  • Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-3%

2 year growth

-3%
Yahoo Finance
Oct 21st, 2026
Pfizer announces layoffs at Rocky Mount and Sanford sites, but gives no numbers

Pfizer has announced layoffs at its Rocky Mount and Sanford facilities in North Carolina, as part of a push to improve efficiency. It told employees of the cuts on Tuesday but did not say how many jobs will go, when, or in which departments. Rocky Mount makes sterile injectables, while Sanford focuses on vaccines and advanced biologics, including gene therapies. "Headcount reductions are a part of this initiative," Pfizer said, adding that it will give affected staff support services. "If indeed this happens, it's going to affect those families," said David Farris, president and chief executive officer of the Rocky Mount Area Chamber of Commerce. The impact on local economies, he said, depends on the number laid off. As of Wednesday afternoon, no Worker Adjustment and Retraining Notification (WARN) notice had been filed with the state.

Yahoo Finance
Oct 19th, 2026
Five low-beta dividend stocks: Pfizer yields 5.83%, Coca-Cola raises payout since 1999

Five defensive dividend stocks offer income with less volatility than the broader market, according to a 24/7 Wall St. analysis. All five have a beta well below 1, meaning they have historically moved less than the market. Pfizer leads with a forward yield of 5.83% at $29.49 a share. AT&T yields 4.77% at $23.27, and its $1.11 dividend uses about 42% of 2026 free cash flow guidance of $18B+. Debt of $144B is its main risk. Dominion Energy yields 4.24%, while Coca-Cola and Colgate-Palmolive each yield 2.27%. Coca-Cola has raised its dividend every year since 1999, and Colgate's next ex-dividend date is October 20, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.

Yahoo Finance
Oct 14th, 2026
Pfizer's 6% dividend pays investors to wait as oncology pipeline drives growth beyond COVID-19

Pfizer offers a dividend yield of just over 6% while it builds growth beyond its COVID-19 products. The drugmaker declared a quarterly dividend of $0.43 in June 2026, its 351st consecutive quarterly payment. In the second quarter, revenue from launched and acquired products rose 18% year over year. Pfizer raised the midpoint of its full-year guidance, helped by stronger non-COVID sales from drugs such as Eliquis, Padcev, and Vyndaqel. Oncology is the next focus. Pfizer is investing in antibody-drug conjugates and bispecific antibodies, and it entered a global collaboration with Innovent Biologics covering 12 early-stage cancer programs. Not every experimental drug will succeed, but a broader pipeline improves the odds. If new medicines work, the share price could rise on top of the dividend income.

Yahoo Finance
Oct 13th, 2026
Six high-yield dividend stocks fail the payout test, from Ford to Whirlpool's 9.37% mirage

High dividend yields can hide weak payouts, and a four-step test helps separate real income from traps. It checks earnings with one-offs stripped out, full-year free cash flow against dividends, management's explanation, and whether debt funds the gap. Ford yields 4.99% and shows a trailing EPS of -$1.88, caused by $4.2B in one-time charges. Its debt-to-equity of 4.66 leaves the $0.60 dividend exposed to a downturn. Pfizer yields 6.03%, but its free cash flow yield is 5.60%. Clorox's roughly $405M of free cash flow fell short of about $601M in dividends. Whirlpool fails every step. It cut its quarterly dividend from $1.75 to $0.90 in 2025, paid no common dividend in the second quarter of 2026, and its shares are down 59.48% since the end of 2025. 3M and Dow pass, with payouts now covered by cash.